Anthropometric outcomes in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective glycemic control from single center


Calapkulu M., CANDER S. , ÖZ GÜL Ö. , ERSOY C.

DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, vol.13, no.1, pp.284-288, 2019 (Journal Indexed in ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 13 Issue: 1
  • Publication Date: 2019
  • Doi Number: 10.1016/j.dsx.2018.09.005
  • Title of Journal : DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS
  • Page Numbers: pp.284-288

Abstract

Introduction: Dapagliflozin is an antidiabetic drug that has been used as a member of the new antidiabetic drug group that acts by inhibiting SGLT-2 and increasing urinary glucose excretion. With numerous controlled experimental studies of dapagliflozin, evaluation of real-life data after entry into clinical practice is an important condition. In our study, the effects of dapagliflozin on glycemic control and anthropometric measurements were investigated retrospectively.